TrialBlood2016

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Paul M Barr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.